How do I set a price alert for IART?

To set a IART price alert on Stock Alarm Pro, navigate to the IART quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for IART?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for IART. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for IART?

Stock Alarm Pro supports over 125 trigger types for IART: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about IART price changes?

IART alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for IART alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for IART and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Integra LifeSciences Holdings Corporation(IART)

$12.92—

WatchlistAsk AI Chart

Integra LifeSciences Holdings Corporation(IART)

NASDAQAbout this data

$12.92—

WatchlistAsk AI Chart Studio

IART(IART)

IART

10/5/26

Integra LifeSciences (IART)

Monday

11:15 AM

ThesisIntegra LifeSciences: the story is balanced — Elective neurosurgery and reconstructive procedure volumes - drives consumable product demand across both segments

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$1.6B	$1.7B	$1.7B
Rev. Growth	+1.5%	+2.1%	+3.2%
EPS	$-6.73	$2.44	$2.60
EPS Growth	-7361%	+136%	+6.5%
P/E (fwd)	—	5.2×	4.9×

★ Analysts see FY2027 revenue reaching $1.7B — +3.2% growth in a single year.

What Moves the Stock

01Elective neurosurgery and reconstructive procedure volumes - drives consumable product demand across both segments
02Hospital capital equipment spending cycles - affects adoption of neuro-monitoring systems and surgical instrument sets
03Wound care reimbursement policy changes - CMS coverage decisions for advanced wound matrices significantly impact Tissue Technologies segment
04Debt refinancing and deleveraging progress - with 1.93x debt/equity and minimal FCF, balance sheet concerns weigh on valuation
05Product pipeline milestones - FDA approvals for new neurosurgery devices or regenerative products can drive growth expectations
06Margin improvement initiatives - cost reduction programs and manufacturing efficiency gains critical given 1.8% operating margin
07Codman Specialty Surgical segment (~55-60% of revenue): neurosurgical instruments, dural repair grafts, neuro-monitoring systems, hydrocephalus shunts
08Tissue Technologies segment (~40-45% of revenue): regenerative wound care products (collagen matrices, skin substitutes), private label surgical products for OEM customers

FY2025 Snapshot

Revenue: $1.6B
Rev. Growth: +1.5%
Gross Margin: 51.7%
Op. Margin: 4.2%
Net Margin: -31.6%
Net Income: $-516M
NI Growth: -7338%
EPS: $-6.73
1Y Return: -13.9%

IART Chart

My Notes

Deep value/distressed investors and special situations funds given the 0.5x sales, 0.8x book valuation and 51% one-year decline.
Rising interest rates negatively impact Integra through multiple channels: (1) higher debt service costs on the company's significant debt…
Watch on earnings: Elective surgery procedure volumes (neurosurgery, plastic/reconstructive) - leading indicator of device demand, Hospital capital equipment spending trends - affects neurosurgery instrument and monitoring system sales, CMS reimbursement rates for advanced wound care products - directly impacts Tissue Technologies pricing power.

One Sentence Summary:

Integra LifeSciences: the story is balanced — elective neurosurgery and reconstructive procedure volumes - drives consumable product demand across both segments.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

—

5.2×

4.9×

What Moves the Stock

01Elective neurosurgery and reconstructive procedure volumes - drives consumable product demand across both segments

02Hospital capital equipment spending cycles - affects adoption of neuro-monitoring systems and surgical instrument sets

03Wound care reimbursement policy changes - CMS coverage decisions for advanced wound matrices significantly impact Tissue Technologies segment

04Debt refinancing and deleveraging progress - with 1.93x debt/equity and minimal FCF, balance sheet concerns weigh on valuation

05Product pipeline milestones - FDA approvals for new neurosurgery devices or regenerative products can drive growth expectations

06Margin improvement initiatives - cost reduction programs and manufacturing efficiency gains critical given 1.8% operating margin

07Codman Specialty Surgical segment (~55-60% of revenue): neurosurgical instruments, dural repair grafts, neuro-monitoring systems, hydrocephalus shunts

08Tissue Technologies segment (~40-45% of revenue): regenerative wound care products (collagen matrices, skin substitutes), private label surgical products for OEM customers

My Notes

Deep value/distressed investors and special situations funds given the 0.5x sales, 0.8x book valuation and 51% one-year decline.

Rising interest rates negatively impact Integra through multiple channels: (1) higher debt service costs on the company's significant debt…

Watch on earnings: Elective surgery procedure volumes (neurosurgery, plastic/reconstructive) - leading indicator of device demand, Hospital capital equipment spending trends - affects neurosurgery instrument and monitoring system sales, CMS reimbursement rates for advanced wound care products - directly impacts Tissue Technologies pricing power.